These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39053329)

  • 1. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.
    Li X; He J; Sun Q
    Clin Nutr; 2024 Sep; 43(9):2005-2016. PubMed ID: 39053329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.
    Malik A; Javaid S; Malik MI; Qureshi S
    Ann Hepatol; 2024 Aug; 29(6):101544. PubMed ID: 39214253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex difference in skeletal muscle mass in relation to metabolic dysfunction-associated steatotic liver disease: a propensity score matching study.
    Son DH; Kwon YJ; Lee JH
    J Nutr Health Aging; 2024 Jun; 28(6):100270. PubMed ID: 38833877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of muscle mass, grip strength and fat-to-muscle ratio and metabolic dysfunction-associated steatotic liver disease in a middle-to-elderly aged population.
    Liu S; He Y; Yu G; Song C; Wang D; Liu L; Liang H; Wan H; Shen J
    Ann Med; 2024 Dec; 56(1):2390169. PubMed ID: 39129458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.
    Sato A; Oomori Y; Nakano R; Matsuura T
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202611
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis.
    Mantovani A; Morandin R; Fiorio V; Lando MG; Petta S; Ferraro PM; Targher G
    Intern Emerg Med; 2024 Sep; 19(6):1745-1755. PubMed ID: 38992323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: A meta-analysis.
    De Filippo O; Di Pietro G; Nebiolo M; Ribaldone DG; Gatti M; Bruno F; Gallone G; Armandi A; Birtolo LI; Zullino V; Mennini G; Corradini SG; Mancone M; Bugianesi E; Iannaccone M; De Ferrari GM; D'Ascenzo F
    Eur J Clin Invest; 2024 Sep; 54(9):e14188. PubMed ID: 38396359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis.
    Lv Q; Zhao H
    Ann Med; 2024 Dec; 56(1):2306192. PubMed ID: 38253023
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioelectrical impedance parameters add incremental value to waist-to-hip ratio for prediction of metabolic dysfunction associated steatotic liver disease in youth with overweight and obesity.
    Song K; Seol EG; Yang H; Jeon S; Shin HJ; Chae HW; Kim EK; Kwon YJ; Lee JW
    Front Endocrinol (Lausanne); 2024; 15():1385002. PubMed ID: 38883602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Singh A; Buckholz A; Kumar S; Newberry C
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):351-358. PubMed ID: 38407898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
    Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
    Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography.
    Kim MJ; Cho YK; Kim EH; Lee MJ; Lee WJ; Kim HK; Jung CH
    J Cachexia Sarcopenia Muscle; 2024 Oct; 15(5):1942-1952. PubMed ID: 39011807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.
    Suvarna R; Shetty S; Pappachan JM
    Sci Rep; 2024 Aug; 14(1):19790. PubMed ID: 39187533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    Wakabayashi SI; Tamaki N; Kimura T; Umemura T; Kurosaki M; Izumi N
    J Gastroenterol; 2024 Jun; 59(6):494-503. PubMed ID: 38570344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis.
    Mantovani A; Lando MG; Borella N; Scoccia E; Pecoraro B; Gobbi F; Bisoffi Z; Valenti L; Tilg H; Byrne CD; Targher G
    Liver Int; 2024 Jul; 44(7):1513-1525. PubMed ID: 38567962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease: A cross-sectional study of NHANES 2017-2018.
    Mai Z; Chen Y; Mao H; Wang L
    J Diabetes; 2024 Jun; 16(6):e13569. PubMed ID: 38751375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.